-transparent.png){kind=logo}
A calcium antagonist, verapamil, enhanced the cellular uptake and cytotoxicity of vincristine (VCR) in adriamycin-resistant P388 leukemia (P388/ADM) cells and also enhanced the cellular uptake and cytotoxicity of adriamycin (ADM) in vincristine-resistant P388 leukemia (P388/VCR) and P388/ADM cells. The enhancement of cytotoxicity and cellular uptake of VCR in P388 and P388/VCR cells has been reported previously. [1]. VCR and ADM resistance was circumvented by verapamil. A common transport mechanism for VCR and ADM, which is responsive to verapamil, seems to exist in VCR- and ADM-resistant cells. However, the enhancement of ADM cytotoxicity and cellular uptake by verapamil was not evident in P388 cells.
T Tsuruo, and
H Iida, and
M Yamashiro, and
S Tsukagoshi, and
Y Sakurai
June 1979,
Cancer research,
T Tsuruo, and
H Iida, and
M Yamashiro, and
S Tsukagoshi, and
Y Sakurai
June 1982,
Journal of the National Cancer Institute,
T Tsuruo, and
H Iida, and
M Yamashiro, and
S Tsukagoshi, and
Y Sakurai
January 1978,
Biochemical pharmacology,
T Tsuruo, and
H Iida, and
M Yamashiro, and
S Tsukagoshi, and
Y Sakurai
January 1988,
Cancer chemotherapy and pharmacology,
T Tsuruo, and
H Iida, and
M Yamashiro, and
S Tsukagoshi, and
Y Sakurai
August 1983,
Cancer research,
T Tsuruo, and
H Iida, and
M Yamashiro, and
S Tsukagoshi, and
Y Sakurai
August 1981,
Biochemical pharmacology,
T Tsuruo, and
H Iida, and
M Yamashiro, and
S Tsukagoshi, and
Y Sakurai
October 1986,
Tumori,
T Tsuruo, and
H Iida, and
M Yamashiro, and
S Tsukagoshi, and
Y Sakurai
April 1989,
Tumori,
T Tsuruo, and
H Iida, and
M Yamashiro, and
S Tsukagoshi, and
Y Sakurai
January 1983,
Oncology,
T Tsuruo, and
H Iida, and
M Yamashiro, and
S Tsukagoshi, and
Y Sakurai
January 1984,
Cancer drug delivery,
